Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin63.5%+5.1pp58.3%-1.9pp60.3%-0.8pp61.1%-7.3pp68.4%-0.5pp
Operating margin-111.2%+48.3pp-159.5%-30.9pp-128.6%-9.4pp-119.2%-43.3pp-75.9%-22.5pp
Net margin-137.1%+51.0pp-188.1%-29.1pp-158.9%-11.6pp-147.4%-47.4pp-100%-23.3pp
Efficiency
Asset turnover0.4×+0.1×0.3×0.0×0.3×-0.1×0.4×-0.1×0.5×-0.3×
Liquidity
Current ratio4.1×+1.0×3.1×-2.8×5.9×+2.4×3.5×-1.3×4.9×+0.2×
Per Share
Book value per share-$0.28+11.8%-$0.31-746%-$0.04+94.9%-$0.73-14.5%-$0.64+8.0%
Valuation
Market capitalization$560.13M+73.5%$788.14M+16.5%$676.24M+112%$318.84M+11.2%$286.73M-11.7%
Price / sales11.1×+5.2×17.7×+2.1×15.6×+8.4×7.2×+1.9×5.3×-0.4×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Aquestive Therapeutics, Inc.'s profit margins?
Aquestive Therapeutics, Inc. (AQST) runs a 63.5% gross margin and a -111.2% operating margin, with a -137.1% net margin.
Where do Aquestive Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Aquestive Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.